El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

Health Effects of Resveratrol: Results from Human Intervention Trials

dc.contributor.authorRamírez-Garza, Sonia L.
dc.contributor.authorLaveriano-Santos, Emily P.
dc.contributor.authorMarhuenda-Muñoz, María
dc.contributor.authorStorniolo, Carolina Emilia
dc.contributor.authorResserra i Rimbau, Anna
dc.contributor.authorVallverdú i Queralt, Anna
dc.contributor.authorLamuela Raventós, Rosa Ma.
dc.date.accessioned2020-04-16T10:18:45Z
dc.date.available2020-04-16T10:18:45Z
dc.date.issued2018-12-03
dc.date.updated2020-04-16T10:18:45Z
dc.description.abstractThe effect of resveratrol (RV) intake has been reviewed in several studies performed in humans with different health status. The purpose of this review is to summarize the results of clinical trials of the last decade, in which RV was determined in biological samples such as human plasma, urine, and feces. The topics covered include RV bioavailability, pharmacokinetics, effects on cardiovascular diseases, cognitive diseases, cancer, type 2 diabetes (T2D), oxidative stress, and inflammation states. The overview of the recent research reveals a clear tendency to identify RV in plasma, showing that its supplementation is safe. Furthermore, RV bioavailability depends on several factors such as dose, associated food matrix, or time of ingestion. Notably, enterohepatic recirculation of RV has been observed, and RV is largely excreted in the urine within the first four hours after consumption. Much of the research on RV in the last 10 years has focused on its effects on pathologies related to oxidative stress, inflammatory biomarkers, T2D, cardiovascular diseases, and neurological diseases
dc.format.extent18 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec683463
dc.identifier.issn2072-6643
dc.identifier.pmid30513922
dc.identifier.urihttps://hdl.handle.net/2445/155517
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/nu10121892
dc.relation.ispartofNutrients, 2018, vol. 10, num. 12, p. 1892
dc.relation.urihttps://doi.org/10.3390/nu10121892
dc.rightscc-by (c) Ramírez-Garza, Sonia L. et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
dc.subject.classificationBiodisponibilitat
dc.subject.classificationObesitat
dc.subject.classificationTrastorns del metabolisme
dc.subject.classificationAntioxidants
dc.subject.classificationFarmacologia
dc.subject.otherBioavailability
dc.subject.otherObesity
dc.subject.otherDisorders of metabolism
dc.subject.otherAntioxidants
dc.subject.otherPharmacology
dc.titleHealth Effects of Resveratrol: Results from Human Intervention Trials
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
683463.pdf
Mida:
1.12 MB
Format:
Adobe Portable Document Format